IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.865
AS - Asia 2.629
EU - Europa 1.080
SA - Sud America 436
Continente sconosciuto - Info sul continente non disponibili 167
AF - Africa 106
OC - Oceania 5
Totale 9.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.736
SG - Singapore 1.539
CN - Cina 517
BR - Brasile 357
IT - Italia 345
VN - Vietnam 218
FI - Finlandia 178
IE - Irlanda 111
DE - Germania 101
CA - Canada 83
HK - Hong Kong 82
NG - Nigeria 65
IN - India 64
GB - Regno Unito 61
FR - Francia 55
NL - Olanda 55
BD - Bangladesh 43
SE - Svezia 40
AR - Argentina 28
JP - Giappone 26
BE - Belgio 21
MX - Messico 21
TR - Turchia 21
IQ - Iraq 18
PL - Polonia 17
RU - Federazione Russa 17
CL - Cile 15
EC - Ecuador 14
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
CO - Colombia 11
ES - Italia 11
PK - Pakistan 11
UA - Ucraina 10
AT - Austria 9
EG - Egitto 9
IL - Israele 9
ZA - Sudafrica 9
AE - Emirati Arabi Uniti 8
ID - Indonesia 8
SA - Arabia Saudita 7
IR - Iran 6
JM - Giamaica 6
KE - Kenya 6
PH - Filippine 6
PT - Portogallo 6
AZ - Azerbaigian 5
EU - Europa 5
KR - Corea 5
MA - Marocco 5
MY - Malesia 5
AU - Australia 4
BG - Bulgaria 4
ET - Etiopia 4
HN - Honduras 4
NP - Nepal 4
PE - Perù 4
VE - Venezuela 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
KG - Kirghizistan 3
LT - Lituania 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AF - Afghanistan, Repubblica islamica di 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
LB - Libano 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 9.126
Salva come PNG Salva come JPEG
Città #
Singapore 687
Dallas 665
Chandler 516
Wilmington 410
Ashburn 350
San Jose 210
The Dalles 199
Shanghai 182
Helsinki 177
San Mateo 162
Milan 154
Beijing 147
Ann Arbor 131
Council Bluffs 124
New York 123
Dublin 109
Boardman 97
Princeton 90
Lawrence 82
Ho Chi Minh City 80
Leawood 77
Santa Clara 77
Benin City 64
Los Angeles 62
Rome 62
Hong Kong 61
Amsterdam 48
Phoenix 48
Hanoi 45
Paris 40
Woodbridge 30
Seattle 29
São Paulo 28
Toronto 28
Buffalo 27
London 26
Fairfield 22
Montreal 20
Pune 20
Brussels 18
Orem 16
San Diego 16
Warsaw 16
Philadelphia 15
Brooklyn 14
Figino 14
Munich 14
Chicago 12
Haiphong 12
Rio de Janeiro 12
Porto Alegre 11
Naples 10
Queens 10
Tashkent 10
Baghdad 9
Boston 9
Chennai 9
Da Nang 9
Kocaeli 9
Tokyo 9
Abbiategrasso 8
Assago 8
Atlanta 8
Columbus 8
Dhaka 8
Frankfurt am Main 8
Manchester 8
Milwaukee 8
Norwalk 8
San Francisco 8
Andover 7
Houston 7
Salvador 7
Turin 7
Belo Horizonte 6
Bogotá 6
Brasília 6
Brno 6
Cairo 6
Charlotte 6
Falkenstein 6
Guayaquil 6
Istanbul 6
Jeddah 6
Kingston 6
Miami 6
Monmouth Junction 6
Raleigh 6
Redwood City 6
Biên Hòa 5
Chengdu 5
Curitiba 5
Denver 5
Florence 5
Jersey City 5
Johannesburg 5
Las Vegas 5
Mexico City 5
Nairobi 5
Phủ Lý 5
Totale 6.016
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 166
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 151
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 139
Tivantinib for hepatocellular carcinoma 132
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 132
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 124
Biomarkers in Hepatocellular Carcinoma-Letter 123
COVID-19 and liver cancer clinical trials: not everything is lost 115
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 115
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 113
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 113
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 112
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 109
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 109
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 109
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 108
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 107
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 107
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 106
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 104
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 103
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 102
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 100
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 99
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 99
Cabozantinib for the treatment of hepatocellular carcinoma 98
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 98
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 96
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 94
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 93
Reply to Y. Pointreau et al 93
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 93
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 92
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 91
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 91
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 91
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 90
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 90
Shaping the landscape of immune oncology in hepatocellular carcinoma 88
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 87
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 87
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 86
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 86
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 85
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 85
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 85
Role of liver biopsy in hepatocellular carcinoma 85
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 84
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 83
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 83
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 83
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 81
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 81
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 81
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 80
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 80
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 80
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 78
Regorafenib for the treatment of unresectable hepatocellular carcinoma 78
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 78
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 78
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 77
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 77
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 77
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 76
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 76
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 76
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 75
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 75
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 75
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 75
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 74
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 74
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 73
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 73
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 71
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 71
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 70
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 69
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 68
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 67
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 67
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 67
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 66
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 66
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 65
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 64
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 64
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 64
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 63
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 63
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 62
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 61
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 60
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 60
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 59
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 58
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 57
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 56
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 56
Totale 8.656
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022538 0 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/20263.634 492 668 176 314 80 157 869 130 175 199 171 203
2026/2027722 428 294 0 0 0 0 0 0 0 0 0 0
Totale 9.288